Changes in Retinal Microvasculature and Visual Acuity After Antivascular Endothelial Growth Factor Therapy in Retinal Vein Occlusion
Investigative Ophthalmology & Visual Science2018Vol. 59(7), pp. 2708–2708
Citations Over TimeTop 10% of 2018 papers
Andrew Winegarner, Taku Wakabayashi, Yoko Fukushima, Tatsuhiko Sato, Chikako Hara-Ueno, Caleb Busch, Issei Nishiyama, Nobuhiko Shiraki, Kaori Sayanagi, Kentaro Nishida, Hirokazu Sakaguchi, Kohji Nishida
Abstract
Anti-VEGF therapy maintains retinal perfusion in most patients with RVO. Preserving retinal perfusion is crucial for better visual outcomes.
Related Papers
- → Clinical correlation to differences in ranibizumab and aflibercept vascular endothelial growth factor suppression times(2016)64 cited
- → UK AMD/DR EMR REPORT IX: comparative effectiveness of predominantly as needed (PRN) ranibizumab versus continuous aflibercept in UK clinical practice(2017)47 cited
- → Neovascular age‐related macular degeneration treated with ranibizumab or aflibercept in the same large clinical setting: visual outcome and number of injections(2016)20 cited
- → CO35 Real-World Effectiveness of Intravitreal Ranibizumab and Aflibercept for Eyes with Central Retinal Vein Occlusion: A Multi-Institutional Cohort Study in Taiwan(2023)
- → Real‐world experience with brolucizumab in pro re nata regimen in patients with neovascular age‐related macular degeneration previously treated with ranibizumab and aflibercept and without control of subretinal fluid(2024)